Last reviewed · How we verify

Pseudomonas Aeruginosa Bronchitis — Treatment Landscape & Competitive Intelligence

Pseudomonas Aeruginosa Bronchitis (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pseudomonas Aeruginosa Bronchitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Azactam AZTREONAM Bristol-Myers Squibb Monobactam Antibacterial [EPC] 1986-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Bristol-Myers Squibb · 1 drug in Pseudomonas Aeruginosa Bronchitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pseudomonas Aeruginosa Bronchitis:

Cite this brief

Drug Landscape (2026). Pseudomonas Aeruginosa Bronchitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pseudomonas-aeruginosa-bronchitis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing